Business Context and Reporting Period
Company: Inovio Pharmaceuticals, Inc. (INO)
Filing Type: Form 8-K (Current Report)
Date of Report: December 29, 2025
Principal Event: Announcement of U.S. Food and Drug Administration (FDA) acceptance of a Biologic License Application (BLA) for INO-3107.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Status
- BLA Acceptance: The FDA accepted the BLA for INO-3107, an investigational immunotherapy for recurrent respiratory papillomatosis (RRP) in adults.
- Review Classification: Standard review.
- PDUFA Date: October 30, 2026 (target date for FDA action).
- Advisory Committee: The FDA is not currently planning to hold an advisory committee meeting.
- Accelerated Approval Pathway: The BLA was filed under the accelerated approval pathway. However, the FDA's file acceptance letter noted a potential review issue regarding the adequacy of information justifying eligibility for this pathway.
Outlook, Management Commentary, and Risks
- Management Action Plan: The Company plans to request a meeting with the FDA to discuss next steps to maintain eligibility under the accelerated approval program.
- Strategic Direction: The Company is not currently planning to seek approval for INO-3107 under the traditional pathway.
- Key Risk: The FDA's preliminary conclusion that the Company has not submitted adequate information to justify the accelerated approval pathway poses a risk to the intended regulatory timeline and approval status.
Investor Verification Checklist
- Verify the outcome of the planned meeting between Inovio and the FDA regarding the accelerated approval eligibility issue.
- Monitor for any FDA requests for additional data or a potential shift to the traditional approval pathway.
- Confirm the status of the PDUFA date (October 30, 2026) in light of the regulatory review issues.
- Review the attached press release (Exhibit 99.1) for further details on the clinical data submitted.